hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06351436, orgStudyIdInfo id: TBC20240402, briefTitle: Virtual Reality Cave Experience With Mindfulness for Mental Wellbeing, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08, primaryCompletionDateStruct date: 2025-08, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: The Hong Kong Polytechnic University, class: OTHER, descriptionModule briefSummary: The aim of this study is to investigate the effectiveness of a mindfulness-based intervention using a virtual reality cave system for promoting mental wellbeing in youths. The mindfulness-based intervention will last for three months, with 6-8 weekly sessions lasting 1.5 hours each. Participants will attend the sessions in a group format, and the sessions will be administered by registered social worker who are specialized in counselling. The intervention content is designed by a registered clinical psychologist accredited for delivering mindfulness-based intervention and nurses who are experienced in mindfulness training.A single-group pre-post uncontrolled design will be employed. Evaluations will be conducted at baseline (0 weeks) and post-intervention (3 months)., conditionsModule conditions: Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Single-group non-randomized uncontrolled trial, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Mindfulness, outcomesModule primaryOutcomes measure: Mental Well-Being in Youths, secondaryOutcomes measure: Stress Level in Youths, secondaryOutcomes measure: Feasibility of Eligibility and Enrollment, secondaryOutcomes measure: Feasibility of Attendance Rate, secondaryOutcomes measure: Feasibility of Retention Rate, eligibilityModule sex: ALL, minimumAge: 11 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06351423, orgStudyIdInfo id: HE-NHS2023/03, briefTitle: The Effectiveness of MIND Diet and Forest Bathing on Stress Reduction, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-29, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Hong Kong Metropolitan University, class: OTHER, descriptionModule briefSummary: This clinical trial aims to explore the effectiveness of the Mediterranean DASH Intervention for Neurodegenerative Delay (MIND) diet and Forest Bathing (FB) in reducing psychological stress among older Chinese individuals. The main questions it aims to answer are:1. what is the effect of FB on stress reduction2. what is the effect of MIND on stress reductionParticipants of the MIND-FB group will participate will receive1. FB: a two-hour FB session on four consecutive weekends in a country park,2. MIND: four nutrition sessions, and adhere to the MIND diet for 12 weeksResearchers will compare the FB and routine care groups to compare the effectiveness of MIND and FB in reducing psychological stress., conditionsModule conditions: Anxiety, conditions: Depression, conditions: Stress, conditions: Psychological Stress, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: a 3-arm randomized controlled study in a parallel design. Eligible participants will be randomly assigned into 3 interventions: (1) FB-MIND, (2) FB and (3) routine care-control., primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Forest Bathing (FB), interventions name: MIND diet, outcomesModule primaryOutcomes measure: Emotional states, secondaryOutcomes measure: Systolic Blood Pressure (SBP), secondaryOutcomes measure: Salivary Cortisol, eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hong Kong Metropolitan University, city: Hong Kong, country: Hong Kong, contacts name: Fabian Ling Ngai Tung, PhD, role: CONTACT, phone: 85239708732, email: ftung@hkmu.edu.hk, contacts name: Fabian Ling Ngai Tung, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Queenie Pui Sze Law, PhD, role: SUB_INVESTIGATOR, contacts name: Katherine Ka Yin Yau, DHsC, role: SUB_INVESTIGATOR, contacts name: Sam Kit San Yuen, role: SUB_INVESTIGATOR, contacts name: Eric Tsz Fai Chan, role: SUB_INVESTIGATOR, geoPoint lat: 22.27832, lon: 114.17469, hasResults: False
protocolSection identificationModule nctId: NCT06351410, orgStudyIdInfo id: JEP 2023-679, briefTitle: Assessment of Tear Production, Corneal Staining, and Comfort Level Wearing Different Types of Contact Lenses, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-02, primaryCompletionDateStruct date: 2024-07-30, completionDateStruct date: 2025-02-28, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: National University of Malaysia, class: OTHER, descriptionModule briefSummary: This research assesses the tear performance of five distinct types of soft contact lenses commonly found in the market. The study involves contact lens participants, all of whom are students enrolled at UKM. Before the study, participants were instructed to discontinue wearing their usual contact lenses for two weeks. The lenses utilized in this clinical trial all possess current refractive power. Participants are required to wear the lenses for an entire day only. Upon completion of the study, participants will be requested to complete a brief questionnaire., conditionsModule conditions: Dry Eye, conditions: Dry Eye Syndromes, conditions: Contact Lens-induced Corneal Fluorescein Staining, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: 18 participants will be fitted with 2 types of lenses on either eye at one time. There will be a 2-week wash-off period before another 2 set of fittings with another 4 types of lenses., primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, maskingDescription: The 6 types of Contact Lenses used will be labeled as A, B, C, D, E, and F by a co-investigator and will be fitted on the participant's eye randomly., enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: Eye Wearing Contact Lens, outcomesModule primaryOutcomes measure: To assess the quantity of tears in eyes wearing contact lenses, primaryOutcomes measure: To asess the quality of tears in eyes wearing contact lenses, primaryOutcomes measure: To assess corneal staining in eyes wearing contact lenses, primaryOutcomes measure: To assess comfort level of participants using CL Discomfort Index Questionaire, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 29 Years, stdAges: ADULT, contactsLocationsModule locations facility: Optometry Clinic, city: Kuala Lumpur, zip: 50300, country: Malaysia, geoPoint lat: 3.1412, lon: 101.68653, documentSection largeDocumentModule largeDocs typeAbbrev: Prot, hasProtocol: True, hasSap: False, hasIcf: False, label: Study Protocol, date: 2024-04-02, uploadDate: 2024-04-01T23:49, filename: Prot_000.pdf, size: 837117, hasResults: False
protocolSection identificationModule nctId: NCT06351397, orgStudyIdInfo id: 75021, briefTitle: Immersive Mixed Reality Simulation to Evoke Empathy, acronym: Empathy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, descriptionModule briefSummary: This is a quantifiable study evaluating the ability of a mixed reality (MR), immersive simulation experience to evoke empathy in anesthesiology trainees. Quantitative methodologies will be employed using standardized questionnaires including the The Jefferson Scale of Physician Empathy for Health Professions Students, (HP-version). Trainees will assess their preliminary, baseline empathy using the Jefferson Scale and after the simulation and debrief, will reassess empathy scores, once again using the Jefferson Scale. A satisfaction survey to assess simulated patient embodiment as a valuable exercise and contributor to empathy education curriculum., conditionsModule conditions: Educational Problems, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: Mixed Reality (MR), outcomesModule primaryOutcomes measure: Changes in self-reported empathy from before and after the simulation, secondaryOutcomes measure: Satisfaction of Design Features of the Simulation, secondaryOutcomes measure: Evaluation of the CHARM system's usability, secondaryOutcomes measure: Evaluation of the CHARM system's ergonomics, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Lucile Packard Children's Hospital Stanford, city: Palo Alto, state: California, zip: 94303, country: United States, contacts name: Astrid Suen, MMedSc, role: CONTACT, email: msuen@stanfordchildrens.org, contacts name: Thomas Caruso, MD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.44188, lon: -122.14302, hasResults: False
protocolSection identificationModule nctId: NCT06351384, orgStudyIdInfo id: 20230744, briefTitle: Early Detection and Risk Stratification of Colorectal Cancer Based on miRNA Platform, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-10-01, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Sir Run Run Shaw Hospital, class: OTHER, descriptionModule briefSummary: This is a prospective, observational cohort study to establish the minimal residual disease (MRD) model for predicting relapse risk and identifying disease recurrence in patients with colorectal adenocarcinoma based on the miRNA platform.Blood miRNA markers will be evaluated. The study will enroll approximately 600 participants, including participants with malignancies or benign diseases, and healthy participants., conditionsModule conditions: Colorectal Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 600, type: ESTIMATED, armsInterventionsModule interventions name: miRNA detection test, outcomesModule primaryOutcomes measure: Correlation between post-surgery 1 month MRD status and recurrence-free survival (RFS) in colorectal patients, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06351371, orgStudyIdInfo id: NCI-2024-01153, secondaryIdInfos id: NCI-2024-01153, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: EAY131-K2, type: OTHER, domain: ECOG-ACRIN Cancer Research Group, secondaryIdInfos id: EAY131-K2, type: OTHER, domain: CTEP, secondaryIdInfos id: U10CA180820, type: NIH, link: https://reporter.nih.gov/quickSearch/U10CA180820, briefTitle: Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2), statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2018-06-19, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute (NCI), class: NIH, descriptionModule briefSummary: This phase II MATCH treatment trial tests how well erdafitinib (JNJ-42756493) works in treating patients with tumors that have FGFR mutations or fusions. Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply. This may help keep cancer cells from growing and may kill them., conditionsModule conditions: Malignant Solid Neoplasm, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: Biopsy, interventions name: Biospecimen Collection, interventions name: Computed Tomography, interventions name: Erdafitinib, interventions name: Magnetic Resonance Imaging, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: 6-month progression-free survival (PFS) rate, secondaryOutcomes measure: Progression free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ECOG-ACRIN Cancer Research Group, city: Philadelphia, state: Pennsylvania, zip: 19103, country: United States, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06351358, orgStudyIdInfo id: GLI.04.US.SL.036, briefTitle: Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-19, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-10-31, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Galderma R&D, class: INDUSTRY, descriptionModule briefSummary: Adult subjects with a history of or currently taking glucagon-like peptide-1 (GLP-1) receptor agonist medication and moderate-to-severe cheek wrinkles and midface contour deficiencies will be treated with Sculptra correction of fine lines and wrinkles in the cheek area and Restylane Lyft or Restylane Contour for cheek augmentation and correction of midface contour deficiencies., conditionsModule conditions: Photoaging, conditions: Weight Loss, conditions: Skin Laxity, conditions: Photodamaged Skin, conditions: Volume Deficiency of the Midface, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Sculptra treatment, interventions name: Restylane Treatment, outcomesModule primaryOutcomes measure: Change in skin hydration from baseline, primaryOutcomes measure: Change in skin radiance from baseline, primaryOutcomes measure: Change in skin elasticity from baseline, primaryOutcomes measure: Change in skin thickness from baseline, secondaryOutcomes measure: Subject Treatment Satisfaction, eligibilityModule sex: ALL, minimumAge: 22 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Somenek + Pittman MD: Advanced Plastic Surgery, status: ENROLLING_BY_INVITATION, city: Washington, state: District of Columbia, zip: 20037, country: United States, geoPoint lat: 38.89511, lon: -77.03637, locations facility: Lorenc Aesthetic Plastic Surgery Center, status: RECRUITING, city: New York, state: New York, zip: 10028, country: United States, contacts name: Paul Lorenc, MD, role: CONTACT, phone: 212-472-2900, email: lorenc@lorenc.com, contacts name: Allison Bonugli, role: CONTACT, email: allison@lorenc.com, contacts name: Paul Z Lorenc, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False
protocolSection identificationModule nctId: NCT06351345, orgStudyIdInfo id: Pro00115215, briefTitle: 129 Xenon Imaging in Patients Treated With Sotatercept, acronym: Sox-PH, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-08-01, completionDateStruct date: 2025-08-01, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Bastiaan Driehuys, class: OTHER, collaborators name: Merck Sharp & Dohme LLC, descriptionModule briefSummary: Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH)., conditionsModule conditions: Pulmonary Hypertension, conditions: Pulmonary Arterial Hypertension, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 14, type: ESTIMATED, armsInterventionsModule interventions name: 129Xe Hyperpolarized, outcomesModule primaryOutcomes measure: Change in Xenon MRI Red Blood Cell (RBC) percentage, primaryOutcomes measure: Change in cardiogenic oscillation amplitudes, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Duke University Medical Center, city: Durham, state: North Carolina, zip: 27710, country: United States, geoPoint lat: 35.99403, lon: -78.89862, hasResults: False
protocolSection identificationModule nctId: NCT06351332, orgStudyIdInfo id: 24-005, briefTitle: A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2027-03-01, completionDateStruct date: 2029-09-01, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Filipa Lynce, MD, class: OTHER, collaborators name: Merck Sharp & Dohme LLC, collaborators name: Zentalis Pharmaceuticals, descriptionModule briefSummary: This research is being done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer.The names of the study drugs involved in this study are:* Azenosertib (a type of WEE1 inhibitor)* Carboplatin (a type of platinum compound)* Pembrolizumab (a type of monoclonal antibody), conditionsModule conditions: Breast Cancer, conditions: Breast Cancer Female, conditions: Triple Negative Breast Cancer, conditions: Hormone Receptor Negative Malignant Tumor Breast Triple, conditions: HER2-negative Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 78, type: ESTIMATED, armsInterventionsModule interventions name: Azenosertib, interventions name: Carboplatin, interventions name: Pembrolizumab, outcomesModule primaryOutcomes measure: Number of Participants Experiencing Dose Limiting Toxicity (DLT), primaryOutcomes measure: Maximum Tolerated Dose (MTD), primaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Clinical Beneficial Rate (CBR), secondaryOutcomes measure: Median Progression Free Survival (PFS), secondaryOutcomes measure: Median Overall Survival (OS), secondaryOutcomes measure: Duration of Response (DOR), secondaryOutcomes measure: Grade 3-5 Treatment-Related Toxicity Rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dana-Farber Cancer Institute, city: Boston, state: Massachusetts, zip: 02215, country: United States, contacts name: Filipa Lynce, MD, role: CONTACT, phone: 617-632-3800, email: Filipa_Lynce@DFCI.HARVARD.EDU, contacts name: Filipa Lynce, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06351319, orgStudyIdInfo id: HenanPPH-zhangquncheng, briefTitle: Endobronchial Ultrasound-based SVM Model for Differentiating Benign and Malignant Mediastinal and Hilar Lymph Nodes, statusModule overallStatus: COMPLETED, startDateStruct date: 2018-01-01, primaryCompletionDateStruct date: 2023-12-01, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Quncheng Zhang, class: OTHER, descriptionModule briefSummary: ABSTRACT Background and objective: To establish a ultrasound radiomics machine learning model based on endobronchial ultrasound (EBUS)to assistdoctors in distinguishing between benign and malignant diagnoses ofmediastinal and hilar lymph nodes.Methods: The clinical and ultrasonic image data of 197 patients wereretrospectively analyzed. The radiomics features were extracted by EBUS.based radiomics and dimensionality reduction was performed on thesefeatures by the least absolute shrinkage and selection operator (LASSO)EBUS-based radiomics model was established by support vector machine(SVM).205 lesions were randomly divided into a training group (n=143)and a validation group (n=62). The diagnostic efficiency was evaluated byreceiver operating characteristic (ROC).Results: A total of 13 stable features with non-zero coefficients wereselected. The support vector machine (SV) model exhibited promisingperformance in both the training and verification groups. In the traininggroup, the SVM model achieved an area under the curve (AUC) of 0.892(95% CI: 0.885-0.899), with an accuracy of 85.3%, sensitivity of 93.2%and specificity of 79.8%.In the verification group, the SVM modeldemonstrated an AUC of 0.906 (95% C: 0.890-0.923),along with anaccuracy of 74.2%,sensitivity of 70.3%, and specificity of 74.1% Conclusion:EBUS-based radiomics model can be used to differentiatemediastinal and hilar benign and malignant lymph nodes. The SVM modeldemonstrates superiority and holds potential as a diagnostic tool in clinical practice, conditionsModule conditions: Benign and Malignant Lymph Nodes, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 197, type: ACTUAL, armsInterventionsModule interventions name: SVM model, outcomesModule primaryOutcomes measure: AUC, primaryOutcomes measure: accuracy, primaryOutcomes measure: sensitivity, primaryOutcomes measure: specificity, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Respiratory and Critical Care Medicine, city: Zhengzhou, state: Henan, zip: 450000, country: China, geoPoint lat: 34.75778, lon: 113.64861, hasResults: False